Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for Tiratricol in Patients with Monocarboxylate Transporter 8 Deficiency Also Known As Allan-Herndon-Dudley Syndrome (AHDS)

Next Previous
Search
Trial Profile

Expanded Access Program for Tiratricol in Patients with Monocarboxylate Transporter 8 Deficiency Also Known As Allan-Herndon-Dudley Syndrome (AHDS)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiratricol (Primary)
  • Indications Allan-Herndon-Dudley syndrome
  • Focus Expanded access; Therapeutic Use
  • Sponsors Egetis Therapeutics

    • Most Recent Events

    • 13 Dec 2023 According to an Egetis Therapeutics media release, the company has partnered with AnovoRx to optimize the execution of and further broaden the outreach and implementation of the EAP for more than 50 additional MCT8 deficiency patients in the USA.
    • 09 Jun 2023 Status changed from planning to recruiting.
    • 26 Apr 2023 According to an Egetis Therapeutics media release, On the request of the FDA Egetis submitted in the fourth quarter of 2022 an Expanded Access Program in the USA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top